Table of contents
November 2006 Vol 6 No 11
From the editors
p825 | doi:10.1038/nrc2028
Research Highlights
Expression profiling: Join the dots...find the bigger picture
p827 | doi:10.1038/nrc2021
Therapy: Barking up the right tree
p828 | doi:10.1038/nrc2017
Trial Watch
Reducing rectal cancer recurrence
p828 | doi:10.1038/nrc2026
Signalling: Strange bedfellows
p829 | doi:10.1038/nrc2022
Tissue morphology: Branching out
p829 | doi:10.1038/nrc2023
Metastasis: A new player
p830 | doi:10.1038/nrc2016
Tumour suppressors: Positive feedback
p830 | doi:10.1038/nrc2024
In the news
Chemo brain imaged
p830 | doi:10.1038/nrc2027
In brief
Chemoresistance | Tumour immunology | Breast cancer | Tumour microenvironment
p831 | doi:10.1038/nrc2025
Leukaemia Stem Cells: Homing in on CD44
p832 | doi:10.1038/nrc2019
Cell death: Fatal cut
p832 | doi:10.1038/nrc2020
Angiogenesis: Blunting the spikes
p833 | doi:10.1038/nrc2018
Reviews
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
Francesco Bertolini, Yuval Shaked, Patrizia Mancuso & Robert S. Kerbel
p835 | doi:10.1038/nrc1971
The number of circulating endothelial cells and their progenitors is increased in some types of cancer, and there is evidence that aspects of these cells might correlate with clinical outcome of cancer patients treated with anti-angiogenic drugs.
Polycomb silencers control cell fate, development and cancer
Anke Sparmann & Maarten van Lohuizen
p846 | doi:10.1038/nrc1991
Polycomb group (PcG) proteins are epigenetic gene silencers that are implicated in neoplastic development. How do PcGs regulate cellular identity, and how might these functions be relevant during tumorigenesis?
MicroRNA signatures in human cancers
George A. Calin & Carlo M. Croce
p857 | doi:10.1038/nrc1997
Research on microRNAs in cancer is moving apace. This Review discusses why miRNA profiling is proving to be a useful new tool for identifying tumour subtypes, and can accurately predict patient outcome. Could miRNAs be exploited to treat tumours?
Selecting targets for cancer prevention: where do we go from here?
Eva Szabo
p867 | doi:10.1038/nrc2008
Given the lack of progress in curing metastatic epithelial cancers, there is intense interest in cancer chemoprevention strategies. However, the serious side effects that have been identified in some cancer prevention trials underscore the need to re-evaluate our approach to clinical chemopreventative drug development.
Perspectives
Opinion
Integration of EGFR inhibitors with radiochemotherapy
Mukesh K. Nyati, Meredith A. Morgan, Felix Y. Feng & Theodore S. Lawrence
p876 | doi:10.1038/nrc1953
Clinical trials have shown that tumours have a modest response to EGFR inhibitors when used alone. Will they prove to be more effective when combined with radiotherapy or chemotherapy or both?
Opinion
Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants
Vered Stearns, Bryan Schneider, N. Lynn Henry, Daniel F. Hayes & David A. Flockhart
p886 | doi:10.1038/nrc1992
Most premenopausal women diagnosed with primary breast cancer receive adjuvant chemotherapy, and many experience chemotherapy-induced ovarian failure (CIOF). Can inherited genetic factors and a better understanding of the biology of CIOF be used to provide optimal counselling for these women?
Essay
Guido Fanconi (1892–1979): a jack of all trades
Stephan Lobitz & Eunike Velleuer
p893 | doi:10.1038/nrc2009
As the eightieth anniversary of the first description of Fanconi anaemia approaches, Stephan Lobitz and Eunike Velleuer look back on his career as a paediatrician and his contribution to cancer research.
